StockWatch
·

Research Reports

12 Aug 2026
MARKSANSMARKSANS PHARMA LTD.

Marksans Q1 FY27: consolidated PAT jumps 174% YoY to ₹159 Cr as NPM expands to ~19%

margin expansion · acquisition led growth · low base yoy

ResultsQ1 FY273 minPharma & Healthcare
MAXHEALTHMax Healthcare Institute Ltd

Max Healthcare Q1 Set to Show Mix-Driven Growth vs. Slowdown Headwind

healthcare earnings · hospital capacity · CGHS pricing

Result previewQ1 FY273 minPharma & Healthcare
11 Aug 2026
AMRUTANJANAMRUTANJAN HEALTH CARE LTD.-$

Amrutanjan Q1 FY27: PAT falls 47% YoY to ₹4.37 Cr as lease-rent hit, hygiene losses widen

fmcg · consumer healthcare · margin compression

ResultsQ1 FY273 minPharma & Healthcare
LAXMIDENTLLaxmi Dental Ltd

Laxmi Dental Q1FY27: consol PAT +24% YoY to ₹10.3 Cr on margin expansion

dental products · aligners business · margin expansion

ResultsQ1 FY273 minPharma & Healthcare
INNOVACAPInnova Captab Ltd

Innova Captab Q1 FY27: consolidated PAT +42% YoY to ₹44.1 Cr, revenue +34%, margins widen

pharma cdmo · branded generics · margin expansion

ResultsQ1 FY273 minPharma & Healthcare
LALPATHLABDr. Lal PathLabs Ltd

Dr. Lal PathLabs: Converging signals of expansion and capital return

diagnostics · expansion · margin

ResearchDeep dive5 minPharma & Healthcare
PREVESTPrevest Denpro Ltd

Prevest Denpro Q1 FY27: consolidated PAT +28% YoY to ₹5.64 Cr, margins expand

dental products · margin expansion · labour code impact

ResultsQ1 FY273 minPharma & Healthcare
VIYASHSEQUENT SCIENTIFIC LTD.

Viyash Scientific Q1 FY27: consolidated PAT ₹79 Cr, up 115% YoY as margins expand

animal health · margin expansion · amalgamation

ResultsQ1 FY273 minPharma & Healthcare
ZYDUSLIFEZydus Lifesciences Ltd

Zydus Q1 FY27: Consolidated PAT Falls 36% YoY to ₹940 Cr Despite 22% Revenue Growth

pharmaceuticals · margin compression · acquisition integration

ResultsQ1 FY273 minPharma & Healthcare
FERMENTAFermenta Biotech Ltd

Fermenta Biotech Q1 FY27: consolidated PAT down 56% YoY as margins nearly halve

vitamin d3 api · bulk drugs chemicals · margin compression

ResultsQ1 FY273 minPharma & Healthcare
GODAVARIBGodavari Biorefineries Ltd

When a Patent Doubles the Stock Price: Godavari's Oncology Inflection

patent · oncology · intellectual property

ResearchDeep dive6 minPharma & Healthcare
MARKSANSMARKSANS PHARMA LTD.

North America momentum carries into Q1; 15–20% FY27 growth on track

pharma · Q1 FY27 · North America growth

Result previewQ1 FY273 minPharma & Healthcare
10 Aug 2026
WOCKPHARMAWOCKHARDT LTD.

Wockhardt Q1 FY27: Consolidated PAT swings to ₹107 Cr from ₹108 Cr loss, revenue up 26%

pharmaceuticals · turnaround · consolidated pat

ResultsQ1 FY273 minPharma & Healthcare
JUBLPHARMAJubilant Pharmova Ltd

Jubilant Pharmova Q1 FY27: PAT Slumps 45% YoY to ₹56 Cr as SPECT Loss Hits Margins

pharma · cdmo · margin compression

ResultsQ1 FY273 minPharma & Healthcare
INDSWFTLABIND-SWIFT LABORATORIES LTD.

Ind-Swift Labs: consolidated PAT jumps 181% YoY to ₹24.68 Cr on sharp margin expansion

pharmaceuticals · margin expansion · ebitda growth

ResultsQ1 FY273 minPharma & Healthcare
TARSONSTarsons Products Ltd

Tarsons swings to ₹1.4 Cr consolidated loss in Q1 FY27 despite 20.7% YoY revenue growth

lab plasticware · margin compression · consolidated loss

ResultsQ1 FY273 minPharma & Healthcare
GLANDGland Pharma Ltd

Gland Pharma Q1 FY27: consolidated PAT up 47% YoY to ₹317 Cr, margins expand to 27%

cdmo growth · margin expansion · us market strength

ResultsQ1 FY273 minPharma & Healthcare
YATHARTHYatharth Hospital & Trauma Care Services Ltd

Yatharth Q1FY27: consolidated PAT +8% YoY as margins compress despite 51% revenue surge

hospitals · healthcare services · margin compression

ResultsQ1 FY273 minPharma & Healthcare
IOLCPIOL CHEMICALS & PHARMACEUTICALS LTD.

IOL Chemicals: consolidated PAT surges 90% YoY to ₹64.4 Cr as revenue jumps 37%, OPM expands

pharma api · chemical segment · margin expansion

ResultsQ1 FY273 minPharma & Healthcare
ASTRAZENASTRAZENECA PHARMA INDIA LTD.

AstraZeneca India Q1 standalone PAT falls 32% YoY to ₹37.9 Cr as margins compress

pharma · margin compression · pat decline

ResultsQ1 FY273 minPharma & Healthcare
SPARCSUN PHARMA ADVANCED RESEARCH COMPANY LTD.

SPARC Q1 loss narrows to ₹20.8 Cr YoY, but the gain is a one-off licensing fee

pharma r&d · one-off revenue · licensing termination

ResultsQ1 FY273 minPharma & Healthcare
LYKALABSLYKA LABS LTD.

Lyka Labs Q1 FY27: consolidated PAT doubles YoY to ₹2.05 Cr as revenue rises 28%

pharmaceuticals · subsidiary divestment · revenue growth

ResultsQ1 FY273 minPharma & Healthcare
KPLKwality Pharmaceuticals Ltd

Kwality Pharma Q1FY27: consolidated PAT surges 115% YoY to ₹25.6 Cr, margins expand, guidance raised

pharma exports · margin expansion · guidance raise

ResultsQ1 FY273 minPharma & Healthcare
GLANDGland Pharma Ltd

Gland Pharma's $90–100M CDMO Prize: When a Pharma Contract Becomes a Business

CDMO · sterile injectables · contract manufacturing

ResearchDeep dive5 minPharma & Healthcare
CAPLIPOINTCAPLIN POINT LABORATORIES LTD.

Sterile Upside: US Momentum Meets Core Growth

Q1 FY27 · sterile injectables · US generics

Result previewQ1 FY273 minPharma & Healthcare
JUBLPHARMAJubilant Pharmova Ltd

CDMO Momentum vs. Quality Headwinds — What to Expect on Aug 10

CDMO · sterile injectables · USFDA warning letter

Result previewQ1 FY273 minPharma & Healthcare
09 Aug 2026
SPARCSUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Back to reality: SPARC reports without the $195M PRV windfall

SPARC · earnings preview · R&D biotech

Result previewQ1 FY273 minPharma & Healthcare
ASTRAZENASTRAZENECA PHARMA INDIA LTD.

Enhertu Ramp & Pricing Headwinds: The Q1 Balancing Act

ASTRAZEN · pharma · earnings preview

Result previewQ1 FY273 minPharma & Healthcare
RUBICONRubicon Research Ltd

Growth levers engaged: Q1 FY27 shapes up as inflection on acquisitions and capacity build

pharma earnings · M&A integration · FDA compliance

Result previewQ1 FY273 minPharma & Healthcare
08 Aug 2026
LALPATHLABDr. Lal PathLabs Ltd

Dr. Lal's Handoff: When the Founder Steps Back, ESOP Keeps the Faith

ESOP · founder succession · diagnostics

ResearchDeep dive6 minPharma & Healthcare